Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mohamed Elshaikh is active.

Publication


Featured researches published by Mohamed Elshaikh.


Lancet Oncology | 2005

Radiotherapy: what can be achieved by technical improvements in dose delivery?

Jean M. Moran; Mohamed Elshaikh; Theodore S. Lawrence

The specialty of radiotherapy has changed rapidly over the past two decades with the development of more sophisticated planning and delivery techniques. These techniques have made it possible to increase safely the radiation dose to the tumour while limiting the dose to surrounding healthy tissues that are sensitive to radiation. Here, we focus on clinical improvements that have been achieved with technological advances in the planning and delivery of radiotherapy and look at the potential for future improvements. It should be noted that improved understanding of the biology underlying the radiation response and the use of chemotherapy and molecularly targeted therapy to enhance radiation sensitivity have contributed equally to the improved outcome of patients undergoing radiotherapy.


Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2007

ACCELERATION OF HYPERFRACTIONATED CHEMORADIATION REGIMEN FOR ADVANCED HEAD AND NECK CANCER

Aaron M. Allen; Mohamed Elshaikh; Francis P. Worden; Carol R. Bradford; Theodoros N. Teknos; Douglas B. Chepeha; Christina Tsien; Laura A Dawson; Susan G. Urba; Gregory T. Wolf; Daniel P. Normolle; Avraham Eisbruch

Our aim was to evaluate the acceleration of a hyperfractionated, concurrent chemoradiation regimen (HxCRT) for advanced head and neck squamous cell carcinoma (HNSCC).


Archive | 2006

Common Radiotherapy Techniques for Spinal Tumors

Mohamed Elshaikh; Roger M. Macklis

Radiation therapy is an important modality in the management of both primary and metastatic tumors involving the spine and spinal cord. The mesenchymal elements of the spinal column and its contents may give rise to a wide variety of primary tumors. Yet, primary neoplastic lesions of the spine are rare, accounting for roughly 5 to 10% of all skeletal tumors. Metastatic lesions of the spine are far more common (1). True spinal cord neoplasms are relatively rare and typically intradural in location. Radiation therapy has evolved over the past decades to better meet these needs. Better pretreatment imaging studies, megavoltage linear accelerators, and computer-based three-dimentional (3D) treatment planning are all improving radiation dose distributions, thus, decreasing the likelihood of severe acute or late toxicity.


International Journal of Radiation Oncology Biology Physics | 2007

MULTI-INSTITUTIONAL ANALYSIS OF LONG-TERM OUTCOME FOR STAGES T1-T2 PROSTATE CANCER TREATED WITH PERMANENT SEED IMPLANTATION

Michael J. Zelefsky; Deborah A. Kuban; Larry B. Levy; Louis Potters; David C. Beyer; John C. Blasko; Brian J. Moran; Jay P. Ciezki; Anthony L. Zietman; Thomas M. Pisansky; Mohamed Elshaikh; Eric M. Horwitz


International Journal of Radiation Oncology Biology Physics | 2005

Matched case–control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: Initial report

Siavash Jabbari; Hyungjin Myra Kim; Mary Feng; Alexander Lin; Christina Tsien; Mohamed Elshaikh; Jeffrey E. Terrel; Carol Anne Murdoch-Kinch; Avraham Eisbruch


International Journal of Radiation Oncology Biology Physics | 2005

Comparison of biochemical failure definitions for permanent prostate brachytherapy

Deborah A. Kuban; Larry B. Levy; Louis Potters; David C. Beyer; John C. Blasko; Brian J. Moran; Jay P. Ciezki; Anthony L. Zietman; Michael J. Zelefsky; Thomas M. Pisansky; Mohamed Elshaikh; Eric M. Horwitz


Annual Review of Medicine | 2006

Advances in radiation oncology

Mohamed Elshaikh; Mats Ljungman; Randall K. Ten Haken; Allen S. Lichter


Archive | 2005

PROPHYLACTIC TAMSULOSIN (FLOMAX) IN PATIENTS UNDERGOING PROSTATE 125 I BRACHYTHERAPY FOR PROSTATE CARCINOMA: FINAL REPORT OF A DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY

Mohamed Elshaikh; James Ulchaker; C.A. Reddy; Kenneth W. Angermeier; Eric A. Klein; Nabil Chehade; Andrew Altman; Jay P. Ciezki


International Journal of Radiation Oncology Biology Physics | 2005

Long-term Multi-institutional Analysis of Stage T1–T2 Prostate Cancer Treated with Permanent Brachytherapy

Michael J. Zelefsky; Deborah A. Kuban; Lawrence B. Levy; Louis Potters; David C. Beyer; J.C. Blasko; Brian J. Moran; Jay P. Ciezki; Anthony L. Zietman; Thomas M. Pisansky; Mohamed Elshaikh; Eric M. Horwitz


International Journal of Radiation Oncology Biology Physics | 2006

2250 : The Impact of Treatment Delay in Patients Receiving Radiation Therapy for Localized Prostate Cancer: A Matched Pair Analysis

Daniel E. Soto; Irwin H. Lee; R. Roberts; Charlie Pan; Mohamed Elshaikh; Michael E. Ray; Patrick W. McLaughlin; Howard M. Sandler

Collaboration


Dive into the Mohamed Elshaikh's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Deborah A. Kuban

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Louis Potters

North Shore-LIJ Health System

View shared research outputs
Top Co-Authors

Avatar

Michael J. Zelefsky

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

John C. Blasko

University of Washington

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge